Does Rallies show 13F holders for NMTC?

Yes. Rallies tracks hedge fund and 13F ownership data for NMTC, including fund names, share counts, latest tracked quarter, and position changes when available.

Is NMTC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NMTC. It does not provide personalized investment advice.

NMTC (NeuroOne Medical Technologies Corporation Common Stock) Stock Analysis - Hedge Fund Holdings

NeuroOne Medical Technologies Corporation Common Stock (NMTC) is a publicly traded Healthcare sector company. As of May 21, 2026, NMTC trades at $4.09 with a market cap of $39.05M and a P/E ratio of -44.56. NMTC moved +0.00% today. Year to date, NMTC is -19.70%; over the trailing twelve months it is +9.66%. Its 52-week range spans $2.37 to $8.34. Analyst consensus is strong buy with an average price target of $9.67. Rallies surfaces NMTC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns NMTC stock?

Hedge funds tracked by Rallies that own NMTC include Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for NeuroOne Medical Technologies Corporation Common Stock.

NMTC Key Metrics

Key financial metrics for NMTC
Metric	Value
Price	$4.09
Market Cap	$39.05M
P/E Ratio	-44.56
EPS	$-0.09
Dividend Yield	0.00%
52-Week High	$8.34
52-Week Low	$2.37
Volume	0
Avg Volume	0
Revenue (TTM)	$9.10M
Net Income	$-3.61M
Gross Margin	56.51%

Top Hedge Funds Holding NMTC

Citadel Advisors holds 81.80K shares of NMTC, changed +20350.50% as of Dec 31, 2024.

Latest NMTC News

NeuroOne Q2 Loss Widens to $11.2M While Cash Fuels Mid-2026 Pilot Study — May 12, 2026
NeuroOne Regains Nasdaq Compliance with 1-for-6 Reverse Split — May 4, 2026
NeuroOne CFO Ron McClurg to Retire June 30, Chris Volker Named Successor — Apr 30, 2026
NeuroOne Announces 1-for-6 Reverse Stock Split Effective April 16 — Apr 14, 2026
NeuroOne Approves 10,000-Share Option at $0.802 Exercise Price — Apr 2, 2026

Recent NMTC Insider Trades

Christianson Mark sold 15.36K (~$11.37K) on Mar 30, 2026.
Christianson Mark sold 100 (~$80) on Mar 13, 2026.
Christianson Mark sold 817 (~$653.6) on Mar 12, 2026.

NMTC Analyst Consensus

3 analysts cover NMTC: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $9.67.

Common questions about NMTC

Who owns NMTC stock?: Hedge funds tracked by Rallies that own NMTC include Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for NeuroOne Medical Technologies Corporation Common Stock.
Does Rallies show 13F holders for NMTC?: Yes. Rallies tracks hedge fund and 13F ownership data for NMTC, including fund names, share counts, latest tracked quarter, and position changes when available.
Is NMTC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NMTC. It does not provide personalized investment advice.